Dr. Melinda Gooderham
Dr. Gooderham is a Dermatologist and Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research. She is an Assistant Professor at Queen’s University and a Consultant Physician at the Peterborough Regional Health Centre. She is a fellow of the Royal College of Physicians and Surgeons of Canada. She received her MD from the University of Western Ontario in 1999, and then completed her Dermatology residency at the University of Toronto in 2004. Prior to training in medicine, Dr. Gooderham obtained a Bachelor of Science from Queen’s University in Kingston in 1992, and a Masters of Science from the University of Guelph in 1995.
Dr. Gooderham is actively involved in teaching medical students, residents, nurse practitioners and physicians both with didactic and clinical hands-on teaching. She practices with a focus on psoriasis, atopic dermatitis, skin cancer and clinical research. She also contributes to several peer-reviewed dermatology publications as an author and reviewer.
Friday NOV 12
Topical Therapy for Psoriasis: Past, Present and Future
- Provide an overview of current topical treatment approaches for the management of PsO
- Discuss the challenges of managing psoriasis across the body using a case-based approach
- Present and review data on emerging therapeutic topical agents for the treatment of PsO
This 30-minute session led by Dr. Melinda Gooderham and Dr. Chih-ho Hong will discuss the approach to managing psoriasis using today’s topical therapies, provide attendees with a framework for enhancing their understanding of the potential use of new topical therapies for the treatment of psoriasis by discussing emerging data and use patient cases to illustrate the present day challenges for Canadian clinicians in managing psoriasis.
Friday NOV 12
Uncovering: Novel Agents, Key Data, and Patient Confidence in AD
This session is a dynamic and interactive program designed to uncover the clinical benefits of novel AD treatments, reveal key data for efficacy outcomes, and includes an interactive discussion on practical applications.
At the end of this program, participants will be able to:
- Define the clinical benefits of novel therapies
- Apply key data for effective outcomes with AD patients
- Explain to patients the mechanism of effect of AD therapy to support body and emotional confidence
Friday NOV 12
Emerging Oral Therapies for the Treatment of Moderate-to-Severe Plaque Psoriasis
This presentation will describe the unmet needs of patients with moderate-to-severe psoriasis and present the latest phase III trials data of emerging targeted oral options (TYK2 inhibitors). It will include interactivity, notably polling questions, a case study, and practical tips.
- Define the existing unmet needs for patients with moderate-to-severe psoriasis and discuss the potential role for emerging targeted oral options o Differentiate the mechanism of action of JAK inhibitors and TYK2 inhibitors
- Review the clinical relevance of the efficacy and safety data for TYK2 inhibitors
- Identify where TYK2 inhibitors fit in treating moderate-to-severe psoriasis